MiniMed Group, Inc. (NASDAQ: MMED) is a Healthcare company (Medical - Equipment & Services) with a market capitalization of $5.0B. The Maz Rating grades it against the other companies in its sector.
MiniMed Group, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $17.78, MiniMed Group, Inc. trades at 1.6x sales and 1.4x book value, with an EV/EBITDA of 28.7. Over the last twelve months it generated about $3.2B of revenue and a net loss of $335M. It runs a gross margin of 53.8%, an operating margin of 0.5% and a net margin of -10.2%. It shows return on equity of -9.1%, return on invested capital of 0.4% and a free cash flow yield of -6.3%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 1.81. Over the past 52 weeks the share price ranged from $10.65 to $24.43, with a beta of -3.71.
MiniMed Group, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MiniMed Group, Inc. specializes in designing, producing, and distributing a broad spectrum of medical technologies and solutions aimed at effective diabetes management. The company's diverse portfolio features essential tools like insulin pumps, continuous glucose monitoring (CGM) systems, infusion sets, specialized software platforms, and various supplementary accessories. These innovations are crafted to enable both patients and healthcare providers to accurately monitor and precisely regulate blood glucose levels. The enterprise was established in 1983 by Alfred E. Mann and is currently headquartered in Northridge, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of July 2026, MiniMed Group, Inc. (MMED) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.11% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.75% / 33% · Receivables / Mkt Cap (36m) 14.2% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.75% / 33.33% · Receivables / Mkt Cap (24m) 14.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.76% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 4.83% / 33.33% · Receivables / Avg Assets (4Q) 12.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 4.39% / 33.33% · (Cash+Recv) / Total Assets 21.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of July 2026, MiniMed Group, Inc. (MMED) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. MiniMed Group, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
MiniMed Group, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated July 31, 2026 (Q1 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.